254 related articles for article (PubMed ID: 10383928)
21. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice.
Barraud de Lagerie S; Comets E; Gautrand C; Fernandez C; Auchere D; Singlas E; Mentre F; Gimenez F
Br J Pharmacol; 2004 Apr; 141(7):1214-22. PubMed ID: 15023856
[TBL] [Abstract][Full Text] [Related]
22. Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests.
South SM; Edwards SR; Smith MT
Clin Exp Pharmacol Physiol; 2009 Jan; 36(1):20-8. PubMed ID: 18671713
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model.
Chen W; Yang JZ; Andersen R; Nielsen LH; Borchardt RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):849-57. PubMed ID: 12388672
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the modulation of P-glycoprotein (P-gp) on the intraocular disposition of its substrate in rabbits.
Senthilkumari S; Velpandian T; Biswas NR; Saxena R; Ghose S
Curr Eye Res; 2008 Apr; 33(4):333-43. PubMed ID: 18398708
[TBL] [Abstract][Full Text] [Related]
25. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.
Edwards JE; Brouwer KR; McNamara PJ
Antimicrob Agents Chemother; 2002 Jul; 46(7):2284-6. PubMed ID: 12069991
[TBL] [Abstract][Full Text] [Related]
26. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.
Chen C; Pollack GM
Pharm Res; 1999 Feb; 16(2):296-301. PubMed ID: 10100317
[TBL] [Abstract][Full Text] [Related]
27. Role of P-glycoprotein in the hepatic metabolism of tacrolimus.
Jeong H; Chiou WL
Xenobiotica; 2006 Jan; 36(1):1-13. PubMed ID: 16507509
[TBL] [Abstract][Full Text] [Related]
28. Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats.
Garrido MJ; Valle M; Calvo R; Trocóniz IF
J Pharmacol Exp Ther; 1999 Jan; 288(1):179-87. PubMed ID: 9862769
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development.
Heinzen EL; Pollack GM
Brain Res; 2004 Oct; 1023(2):175-84. PubMed ID: 15374743
[TBL] [Abstract][Full Text] [Related]
30. Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
Sadiq MW; Salehpour M; Forsgard N; Possnert G; Hammarlund-Udenaes M
Drug Metab Dispos; 2011 Feb; 39(2):174-9. PubMed ID: 21059857
[TBL] [Abstract][Full Text] [Related]
31. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
[TBL] [Abstract][Full Text] [Related]
32. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
[TBL] [Abstract][Full Text] [Related]
33. Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling.
Gardmark M; Karlsson MO; Jonsson F; Hammarlund-Udenaes M
J Pharm Sci; 1998 Jul; 87(7):813-20. PubMed ID: 9649348
[TBL] [Abstract][Full Text] [Related]
34. The complexity of intestinal absorption and exsorption of digoxin in rats.
Yao HM; Chiou WL
Int J Pharm; 2006 Sep; 322(1-2):79-86. PubMed ID: 16781832
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.
Kaddoumi A; Choi SU; Kinman L; Whittington D; Tsai CC; Ho RJ; Anderson BD; Unadkat JD
Drug Metab Dispos; 2007 Sep; 35(9):1459-62. PubMed ID: 17591677
[TBL] [Abstract][Full Text] [Related]
36. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
37. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier.
Cutler L; Howes C; Deeks NJ; Buck TL; Jeffrey P
J Pharm Sci; 2006 Sep; 95(9):1944-53. PubMed ID: 16850390
[TBL] [Abstract][Full Text] [Related]
38. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline passes through the blood-brain barrier of rat brain: an in vivo microdialysis study.
Song Y; Feng Y; Leblanc MH; Castagloni N; Liu YM
Neurosci Lett; 2006 Feb; 395(1):63-6. PubMed ID: 16289318
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice.
Park S; Sinko PJ
J Pharmacol Exp Ther; 2005 Mar; 312(3):1249-56. PubMed ID: 15528451
[TBL] [Abstract][Full Text] [Related]
40. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier.
Ejsing TB; Linnet K
Hum Psychopharmacol; 2005 Mar; 20(2):149-53. PubMed ID: 15624117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
